Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species

J. Brett Heimlich, Joshua S. Speed, Paul M O'Connor, Jennifer S. Pollock, Tim M. Townes, Steffen E Meiler, Abdullah Kutlar, David M. Pollock

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background and Purpose Endothelin-1 (ET-1) is increased in patients with sickle cell disease and may contribute to the development of sickle cell nephropathy. The current study was designed to determine whether ET-1 acting via the ETA receptor contributes to renal injury in a mouse model of sickle cell disease. Experimental Approach Adult, humanized HbSS (homozygous for sickle Hb) mice had increased ET-1 mRNA expression in both the cortex and the glomeruli compared with mice heterozygous for sickle and Hb A (HbAS controls). In the renal cortex, ETA receptor mRNA expression was also elevated in HbSS (sickle) mice although ETB receptor mRNA expression was unchanged. Ligand binding assays confirmed that sickle mice had increased ETA receptors in the renal vascular tissue when compared with control mice. Key Results In response to PKC stimulation, reactive oxygen species production by isolated glomeruli from HbSS sickle mice was increased compared with that from HbSA controls, an effect that was prevented by 1 week in vivo treatment with the selective ETA antagonist, ABT-627. Protein and nephrin excretion were both elevated in sickle mice, effects that were also significantly attenuated by ABT-627. Finally, ETA receptor antagonism caused a significant reduction in mRNA expression of NADPH oxidase subunits, which may contribute to nephropathy in sickle cell disease. Conclusions and Implications These data support a novel role for ET-1 in the progression of sickle nephropathy, specifically via the ETA receptor, and suggest a potential role for ETA receptor antagonism in a treatment strategy.

Original languageEnglish (US)
Pages (from-to)386-395
Number of pages10
JournalBritish Journal of Pharmacology
Volume173
Issue number2
DOIs
StatePublished - Jan 1 2016

Fingerprint

Sickle Cell Anemia
Endothelin-1
Reactive Oxygen Species
Kidney
Wounds and Injuries
Messenger RNA
NADPH Oxidase
Blood Vessels
Ligands

ASJC Scopus subject areas

  • Pharmacology

Cite this

Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species. / Brett Heimlich, J.; Speed, Joshua S.; O'Connor, Paul M; Pollock, Jennifer S.; Townes, Tim M.; Meiler, Steffen E; Kutlar, Abdullah; Pollock, David M.

In: British Journal of Pharmacology, Vol. 173, No. 2, 01.01.2016, p. 386-395.

Research output: Contribution to journalArticle

Brett Heimlich, J. ; Speed, Joshua S. ; O'Connor, Paul M ; Pollock, Jennifer S. ; Townes, Tim M. ; Meiler, Steffen E ; Kutlar, Abdullah ; Pollock, David M. / Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species. In: British Journal of Pharmacology. 2016 ; Vol. 173, No. 2. pp. 386-395.
@article{896cbaa2a7504b50a1f728514d9157ca,
title = "Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species",
abstract = "Background and Purpose Endothelin-1 (ET-1) is increased in patients with sickle cell disease and may contribute to the development of sickle cell nephropathy. The current study was designed to determine whether ET-1 acting via the ETA receptor contributes to renal injury in a mouse model of sickle cell disease. Experimental Approach Adult, humanized HbSS (homozygous for sickle Hb) mice had increased ET-1 mRNA expression in both the cortex and the glomeruli compared with mice heterozygous for sickle and Hb A (HbAS controls). In the renal cortex, ETA receptor mRNA expression was also elevated in HbSS (sickle) mice although ETB receptor mRNA expression was unchanged. Ligand binding assays confirmed that sickle mice had increased ETA receptors in the renal vascular tissue when compared with control mice. Key Results In response to PKC stimulation, reactive oxygen species production by isolated glomeruli from HbSS sickle mice was increased compared with that from HbSA controls, an effect that was prevented by 1 week in vivo treatment with the selective ETA antagonist, ABT-627. Protein and nephrin excretion were both elevated in sickle mice, effects that were also significantly attenuated by ABT-627. Finally, ETA receptor antagonism caused a significant reduction in mRNA expression of NADPH oxidase subunits, which may contribute to nephropathy in sickle cell disease. Conclusions and Implications These data support a novel role for ET-1 in the progression of sickle nephropathy, specifically via the ETA receptor, and suggest a potential role for ETA receptor antagonism in a treatment strategy.",
author = "{Brett Heimlich}, J. and Speed, {Joshua S.} and O'Connor, {Paul M} and Pollock, {Jennifer S.} and Townes, {Tim M.} and Meiler, {Steffen E} and Abdullah Kutlar and Pollock, {David M.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/bph.13380",
language = "English (US)",
volume = "173",
pages = "386--395",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species

AU - Brett Heimlich, J.

AU - Speed, Joshua S.

AU - O'Connor, Paul M

AU - Pollock, Jennifer S.

AU - Townes, Tim M.

AU - Meiler, Steffen E

AU - Kutlar, Abdullah

AU - Pollock, David M.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background and Purpose Endothelin-1 (ET-1) is increased in patients with sickle cell disease and may contribute to the development of sickle cell nephropathy. The current study was designed to determine whether ET-1 acting via the ETA receptor contributes to renal injury in a mouse model of sickle cell disease. Experimental Approach Adult, humanized HbSS (homozygous for sickle Hb) mice had increased ET-1 mRNA expression in both the cortex and the glomeruli compared with mice heterozygous for sickle and Hb A (HbAS controls). In the renal cortex, ETA receptor mRNA expression was also elevated in HbSS (sickle) mice although ETB receptor mRNA expression was unchanged. Ligand binding assays confirmed that sickle mice had increased ETA receptors in the renal vascular tissue when compared with control mice. Key Results In response to PKC stimulation, reactive oxygen species production by isolated glomeruli from HbSS sickle mice was increased compared with that from HbSA controls, an effect that was prevented by 1 week in vivo treatment with the selective ETA antagonist, ABT-627. Protein and nephrin excretion were both elevated in sickle mice, effects that were also significantly attenuated by ABT-627. Finally, ETA receptor antagonism caused a significant reduction in mRNA expression of NADPH oxidase subunits, which may contribute to nephropathy in sickle cell disease. Conclusions and Implications These data support a novel role for ET-1 in the progression of sickle nephropathy, specifically via the ETA receptor, and suggest a potential role for ETA receptor antagonism in a treatment strategy.

AB - Background and Purpose Endothelin-1 (ET-1) is increased in patients with sickle cell disease and may contribute to the development of sickle cell nephropathy. The current study was designed to determine whether ET-1 acting via the ETA receptor contributes to renal injury in a mouse model of sickle cell disease. Experimental Approach Adult, humanized HbSS (homozygous for sickle Hb) mice had increased ET-1 mRNA expression in both the cortex and the glomeruli compared with mice heterozygous for sickle and Hb A (HbAS controls). In the renal cortex, ETA receptor mRNA expression was also elevated in HbSS (sickle) mice although ETB receptor mRNA expression was unchanged. Ligand binding assays confirmed that sickle mice had increased ETA receptors in the renal vascular tissue when compared with control mice. Key Results In response to PKC stimulation, reactive oxygen species production by isolated glomeruli from HbSS sickle mice was increased compared with that from HbSA controls, an effect that was prevented by 1 week in vivo treatment with the selective ETA antagonist, ABT-627. Protein and nephrin excretion were both elevated in sickle mice, effects that were also significantly attenuated by ABT-627. Finally, ETA receptor antagonism caused a significant reduction in mRNA expression of NADPH oxidase subunits, which may contribute to nephropathy in sickle cell disease. Conclusions and Implications These data support a novel role for ET-1 in the progression of sickle nephropathy, specifically via the ETA receptor, and suggest a potential role for ETA receptor antagonism in a treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=84953348966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953348966&partnerID=8YFLogxK

U2 - 10.1111/bph.13380

DO - 10.1111/bph.13380

M3 - Article

C2 - 26561980

AN - SCOPUS:84953348966

VL - 173

SP - 386

EP - 395

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -